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TO THE EDITOR
Chronic spontaneous urticaria (CSU) is
characterized by short-lived itchy
wheals, angioedema, or both for more
than 6 weeks. Symptoms of CSU are
mainly mediated by the release of
histamine from mast cells, but as of yet
it is not entirely understood how mast
cells get activated in CSU. In most
CSU patients, underlying causes such
as intolerance to foodstuff, chronic
infections, or autoreactivity (ie due to
circulating IgG anti-FceRI, IgG anti-IgE,
or IgE antibodies to autoantigens) can
be identified (Grattan et al., 1986;
Gruber et al., 1988; Hide et al., 1993;
Wedi et al., 1998; Magerl et al., 2010;
Altrichter et al., 2011; Hatada et al.,
2013; Zuberbier et al., 2014). Why
some people in whom these potential
causes are found develop urticaria
and others don’t is unclear, as is the
question why CSU shows spontaneous
remission at some point.
Disease activity of CSU is assessed
using the UAS (urticaria activity score)
and the AAS (angioedema activity score),
and the impact of CSU on quality of life
is assessed using the CU-Q2oL (chronic
urticaria quality of life questionnaire) and
the AE-QoL (angioedema quality of life
questionnaire) (Zuberbier et al., 2014).
The recently introduced urticaria control
test (UCT) enables a quick assessment of
treatment efficacy and disease control
(Weller et al., 2014). All of these tools
are, however, based on the subjective
assessment of symptoms by the patient,
and there is currently no objective
measure to assess disease activity or
severity. We and others have tried in
the past to identify biomarkers in CSU.
Among these, D-dimer has been shown
to correlate with disease severity and to
be especially high in antihistamine-resis-
tant urticaria (Asero et al., 2008; Asero,
2013). However, plasma D-dimer
concentrations are known to be rather
nonspecific as they are known to be
elevated in various inflammatory
processes. A good biomarker in CSU
should be elevated (only) in CSU
patients and correlate with disease
activity. As of yet, no good biomarker
has been reported and confirmed by
independent studies (Metz et al., 2013).
We hypothesized that Substance P
(SP), an 11-amino-acid peptide that acts
primarily via the G-protein-coupled
receptor neurokinin-1, could be both a
biomarker and a factor involved in the
pathogenesis of CSU since (1) at high
concentrations, SP can induce the
degranulation of mast cells in vitro
(Kulka et al., 2008); (2) SP induces a
wheal and flare response in vivo, which
is more pronounced in patients with
CSU as compared to healthy controls
(Borici-Mazi et al., 1999); and (3) low
concentrations of SP, ie, concentrations
that are likely to occur in the skin of
patients, can increase the responsive-
ness of mast cells to activating signals
(Janiszewski et al., 1994; Forsythe and
Bienenstock, 2012).
To assess whether SP is a good
biomarker in CSU, we first compared
serum concentrations of SP in samples
from 30 healthy subjects with 118 CSU
patients from two independent urticaria
clinics in Germany and observed a
significant and more than fourfold
increase in SP levels in patients with
CSU (491±24 pg ml1) compared to
healthy controls (105±28 pg ml1,
Po0.0001, Figure 1a). Additionally,
we have assessed SP levels in the
serum of 20 patients with cold urticaria.
Here, SP levels are also increased
(280.3±24 pg ml1), but significantly
lower than in CSU patients (Figure 1a).
All analyses have been carried out in
adherence to the Helsinki Guidelines
and after institutional approval with
written and informed patient consent.
Next, using the UAS7 as activity
marker, we found a significant correla-
tion between SP and disease activity
(Figure 1b). Furthermore, very high
levels of SP (4800 pg ml1) were absent
in healthy subjects and in mild CSU but
found in every fourth patient with severe
CSU (26%), while low levels of SP were
predominant in healthy controls (77%)
and rarely found in severe CSU patients
(13%, Figure 1c). It has been shown that
mast cells can be a source of SP
(Katsuno et al., 2003); hence it can be
speculated that elevated SP is due to
massive mast cell degranulation in
patients with high UAS. To address this
possibility, we have correlated SP level
with urticaria activity at the day of blood
withdrawal, which did not reveal signi-
ficant differences (Figure 1d), indicating
that elevated SP levels in CSU patients are
not due to SP released from mast cells.
It has been hypothesized that SP is
involved in the pathogenesis of angioe-
dema in CSU (Akcali et al., 2008).
We, therefore, compared patients with
(n¼ 48) or without (n¼11) angioe-
dema and did not detect differences in
SP levels between these groups
(Figure 2a). Furthermore, comparison
of SP levels among CSU patients based
on the underlying etiology of CSU
showed no differences between these
groups (Figure 2b).
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CSU patients have a high prevalence
of psychosomatic comorbidity and often
report exacerbation of disease under
stress (Staubach et al., 2006). As SP
has been implicated not only in
inflammatory diseases but also in the
pathophysiology of depression and
anxiety (Rosenkranz, 2007); we next
examined SP in patients with or
without increased levels of anxiety,
depressive mood, or history of
exacerbation of disease in stress. In the
investigated population, we did not
observe differences in SP between
either group (Figure 2c and d). To rule
out other potential bias, we also corre-
lated SP levels with duration of disease
and with the age and sex of the CSU
patients. As expected, no correlation
was observed for any of these groups
(data not shown).
Here, we show that SP is increased
in CSU patients and that only disease
activity but not underlying cause of
disease, occurrence of angioedema, or
psychosomatic comorbidities are corre-
lated with serum concentrations of SP.
Whether SP also contributes to the
pathophysiology of CSU is as of yet
unclear and cannot be answered by
our findings. However, hints from the
literature allow us to hypothesize about
a potential role of SP: Unlike human
skin mast cells, mucosal mast cells in
the intestine do not constitutively
express neurokinin-1, the main receptor
for SP (Bischoff et al., 2004). Urticaria
symptoms are mainly restricted to the
skin, and despite the abundance of mast
cells in the intestine urticaria does
usually not affect the gastrointestinal
tract. A role for SP in urticaria could
explain this phenomenon. Furthermore,
SP has been shown to act as a sensitizer
for mast cells, i.e., increased SP levels
may reduce the activation threshold of
mast cells (Janiszewski et al., 1994;
Zuberbier et al., 2002; Forsythe and
Bienenstock, 2012). Here, we have
identified elevated SP regardless of the
underlying cause of urticaria. We could
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Figure 1. Substance P is markedly increased in chronic spontaneous urticaria (CSU) and correlates with disease activity. Substance P was measured by
ELISA (R&D Systems, Minneapolis, MN) in the serum of CSU patients (n¼ 118), age- and sex-matched healthy controls (n¼ 30), and patients with cold urticaria
(n¼ 20). (a) Whiskers show 5–95th percentiles, with the dots representing outliers; ***Po0.001 vs. ‘Healthy’ and þ þ þPo0.001 vs. cold urticaria. (b) The urticaria
activity score (UAS7) was calculated as a weekly score (minimum 0, maximum 42) and a linear regression was used to correlate Substance P levels with
UAS. (c) Patients were arbitrarily categorized into mild, moderate, and severe CSU based on their UAS (mild 1–15, moderate 16–29, severe 30–42), and the
percentage of patients showing low, medium, or high levels of substance P is shown. Total numbers are given in brackets. (d) The urticaria activity score (UAS) at
the time of blood withdrawal was calculated from the score at the day of blood withdrawal (minimum 0, maximum 6). The number of patients is shown in
parentheses; n.s.¼no significance between any of the UAS groups, ***Po0.001 vs. each of the UAS groups.
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thus hypothesize that elevated SP may
be a unifying underlying sensitizer
enabling other factors (e.g., comple-
ment, pseudoallergens, autoreactive
substances) to reach threshold levels
for activating mast cells.
In a previous report, SP has not been
found to be elevated in CSU (Tedeschi
et al., 2005). In our hands there was a
very robust and reproducible upregu-
lation of SP in CSU patients from two
independent centres as compared to
healthy controls; we can therefore not
explain this discrepancy. However, it
has been shown before that bovine SP
is markedly reduced in blood samples
processed within 1 hour because of
rapid degradation by enzymes (Mosher
et al., 2014). To avoid degradation of
SP, we have processed blood within
30 minutes and stored serum at
 80 1C. Possibly, differences in the
blood processing have resulted in the
observed discrepancies. Furthermore,
we compared SP levels in serum with
or without the addition of the enzyme
inhibitor aprotinin and EDTA and did
not observe differences in SP concen-
trations (data not shown).
Taken together, our results indicate
that SP has the potential to be used
as a biomarker in CSU and that it could
be a therapeutic target in CSU treat-
ment.
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Figure 2. Substance P is elevated independently of co-factors present in chronic spontaneous urticaria (CSU) patients. Some patients underwent
extensive diagnostic work-up, including pseudoallergen- and histamine-low diet, search for infections (i.e., ear, nose and throat, teeth, gastrointestinal), and
autologous serum skin test, to identify the underlying etiology of CSU, and questionnaires such as the Hospital Anxiety and Depression Scale (HADS) to assess
potential psychosomatic comorbidities. Overall, no differences in substance P expression were observed (a) depending on whether patients developed wheals
with (n¼ 11) or without (n¼ 48) angioedema; (b) depending on the underlying cause of CSU (n given in parentheses); (c, d) depending on whether patients showed
low (0–7) or high (8–15) values on the anxiety (n¼ 69 and 9, respectively (c)) or the depression scale (n¼72 and 6, respectively (d)) of the Hospital Anxiety
and Depression Scale (HADS); and (e) independent of whether patients answered ‘yes’ (n¼ 20) or ‘no’ (n¼ 17) to the question if stress induces or exacerbates their
symptoms.
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TO THE EDITOR
Cutis laxa (CL) is a heterogeneous group
of disorders characterized by loose,
redundant, inelastic, or prematurely
wrinkled skin (Berk et al., 2012; Uitto
et al., 2013). Several inherited forms
of CL have been identified (Urban and
Davis, 2014), with nine causative genes
known to date (ALDH18A1, ATP6V0A2,
ATP7A, EFEMP2/FBLN4, ELN, FBLN5,
LTBP4, PYCR1, RIN2). A shared feature
of all types of inherited CL is a reduced
or abnormal deposition of elastic fibers
in the skin and other tissues (Berk
et al., 2012). The consequences of
this disorder for the biomechanics of
the skin has received little attention
(Grahame and Beighton, 1971). Such
studies are essential for a fundamental
understanding of the contribution of
elastic fibers to the mechanical proper-
ties of the skin, and for an improved,
objective diagnosis of CL.
In the present study, 118 participating
controls and 17 CL patients were inclu-
ded with informed, written consent. The
same control cohort was used in a
concurrent study on the mechanical
properties of the skin in Williams–
Beuren syndrome (Kozel et al., 2014).
Table 1. Demography and elasticity parameters in the participants
Controls (n¼ 118) Patients (n¼ 17) P-value
Age 33.22±1.58 29.21±5.47 0.490a
Gender (male %) 37.3% 35.3% 0.874b
E (MPa) 11.61±0.15 7.85±0.60 o0.0001a
Retraction time (ms) 622.82±21.20 1,152.82±211.21 0.024a
VE (MPa) 5.35±0.14 2.51±0.32 o0.0001a
Abbreviations: E, elastic modulus; VE, viscoelastic modulus.
Continuous variables: mean±standard error of mean.
aIndependent t-test.
bChi-square test.
Accepted article preview online 20 May 2014; published online 26 June 2014
Abbreviations: ADCL, autosomal dominant cutis laxa; CL, cutis laxa; E, elastic modulus; ROC, receiver
operating characteristic; RT, retraction time; VE, viscoelastic modulus
BA Kozel et al.
Skin Biomechanics in CL
2836 Journal of Investigative Dermatology (2014), Volume 134
